Cardiovascular Diseases

Cardiovascular Disease
Cardiovascular Disease.ppt

Fitness and Health for Scuba
Fitness and Health for Scuba.ppt

Prevalence of Cardiovascular Disease in U.S.
Prevalence of Cardiovascular Disease.ppt

Body Regions and Directions
The_Human_Body.ppt

Ulnar Collateral Ligament Rehabilitation
Michael Cox
Ulnar Collateral Ligament Rehabilitation.ppt

What happens to broken hearts? Takotsubo Cardiomyopathy
Tristah Romero
What happens to broken hearts.ppt

Foodborne Contaminants
Foodborne Contaminants.ppt

Antilipemic Agents
Antilipemic_agents.ppt

Beta- Thalassemia: A Common Blood Disorder
Beta- Thalassemia.ppt
400 free full text articles

1. Comparisons of established risk prediction models for cardiovascular disease: systematic review.
2. Preventing a Cardiovascular Disease Epidemic among Indigenous Populations through Lifestyle Changes.
3. Trends in cardiovascular disease biomarkers and their socioeconomic patterning among adults in the Scottish population 1995 to 2009: cross-sectional surveys.
4. Cohort studies of cardiovascular disease in the Seychelles, Tanzania and Mauritius.
5. Novel miniature mobile cardiac catheterization laboratory for critical cardiovascular disease following natural disasters: a feasibility study.
6. Alcohol and cardiovascular disease-modulation of vascular cell function.
7. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients.
8. Cardiovascular Disease.
9. Vitamin D deficiency is an independent risk factor for cardiovascular disease in Koreans aged ≥ 50 years: results from the Korean National Health and Nutrition Examination Survey.
10. A prospective randomized controlled trial of the effects of vitamin d supplementation on cardiovascular disease risk.
11. Neuroprotection and neurodegeneration in Alzheimer's disease: role of cardiovascular disease risk factors, implications for dementia rates, and prevention with aerobic exercise in african americans.
12. The Emerging Role of TLR and Innate Immunity in Cardiovascular Disease.
13. Cardiovascular Disease in Blacks with HIV/AIDS in the United States: A Systematic Review of the Literature.
14. Use of Serum Homocysteine to Predict Cardiovascular Disease in Korean Men with or without Metabolic Syndrome.
15. Role of advanced glycation end products in cardiovascular disease.
16. Differences in cardiovascular disease risk factors associated with maximum and mean carotid intima-media thickness among hemodialysis patients.
17. Controlled Exposure Study of Air Pollution and T Wave Alternans in Volunteers without Cardiovascular Disease.
18. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.
19. Effectiveness of Dader Method for Pharmaceutical Care on Control of Blood Pressure and Total Cholesterol in Outpatients with Cardiovascular Disease or Cardiovascular Risk: EMDADER-CV Randomized Controlled Trial.
20. Clinical perspectives of urocortin and related agents for the treatment of cardiovascular disease.
21. Mammalian Target of Rapamycin Signaling in Diabetic Cardiovascular Disease.
22. The use of complementary and alternative medicine by people with cardiovascular disease: a systematic review.
23. The Myocardial Unfolded Protein Response during Ischemic Cardiovascular Disease.
24. The mediterranean diet pattern and its main components are associated with lower plasma concentrations of tumor necrosis factor receptor 60 in patients at high risk for cardiovascular disease.
25. The Interface between Inflammation and Coagulation in Cardiovascular Disease.
26. Blood Pressure Reactivity to an Anger Provocation Interview Does Not Predict Incident Cardiovascular Disease Events: The Canadian Nova Scotia Health Survey (NSHS95) Prospective Population Study.
27. An epidemiologic transition of cardiovascular disease risk in carriacou and petite martinique, grenada: the grenada heart project, 2005-2007.
28. Peptide mimotopes of malondialdehyde-epitopes for clinical applications in cardiovascular disease.
29. Primary and secondary prevention of cardiovascular disease in diabetes with aspirin.
30. Risk factors for cardiovascular disease and type 2 diabetes retained from childhood to adulthood predict adult outcomes: the Princeton LRC Follow-up Study.
31. A retrospective cohort study assessing patient characteristics and the incidence of cardiovascular disease using linked routine primary and secondary care data.
32. Human resistin in cardiovascular disease.
33. Cardiovascular disease risk factor patterns and their implications for intervention strategies in Vietnam.
34. Sex differences in risk factors for cardiovascular disease: the PERU MIGRANT study.
35. The role and clinical significance of high-sensitivity C-reactive protein in cardiovascular disease.
36. No significant improvement of cardiovascular disease risk indicators by a lifestyle intervention in people with Familial Hypercholesterolemia compared to usual care: results of a randomised controlled trial.
37. Coronary Artery Calcification by Computed Tomography in Epidemiologic Research and Cardiovascular Disease Prevention.
38. Traditional dietary recommendations for the prevention of cardiovascular disease: do they meet the needs of our patients?
39. Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis.
40. Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease - A cost-effectiveness analysis.
41. Evaluation of oxidative stress and antioxidant status in patients with cardiovascular disease in rural populations of the nilgiris, South India.
42. Morusinol Extracted from Morus Alba Inhibits Arterial Thrombosis and Modulates Platelet Activation for the Treatment of Cardiovascular Disease.
43. Individual-based Primary prevention of Cardiovascular Disease in Cambodia and Mongolia: early identification and management of hypertension and diabetes mellitus.
44. Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
45. Physical activity and risk of cardiovascular disease--a meta-analysis of prospective cohort studies.
46. Associations between screen-based sedentary behavior and cardiovascular disease risk factors in Korean youth.
47. The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings.
48. Cardiovascular disease risk profile and microvascular complications of diabetes: comparison of Indigenous cohorts with diabetes in Australia and Canada.
49. In-home solid fuel use and cardiovascular disease: a cross-sectional analysis of the Shanghai Putuo study.
50. Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan.
51. Self-Reported Snoring Frequency and Incidence of Cardiovascular Disease: The Circulatory Risk in Communities Study (CIRCS).
52. Restless legs syndrome and risk of incident cardiovascular disease in women and men: prospective cohort study.
53. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease.
54. Cardiovascular disease and air pollution in Scotland: no association or insufficient data and study design?
55. [Cost of drugs used to treat cardiovascular disease in Brazil].
56. Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference.
57. Homocysteine, grey matter and cognitive function in adults with cardiovascular disease.
58. Indoor physical activity reduces all-cause and cardiovascular disease mortality among elderly women.
59. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study.
60. Dietary fiber and saturated fat intake associations with cardiovascular disease differ by sex in the Malmö Diet and Cancer Cohort: a prospective study.
61. Putting genome analysis to good use: lessons from C-reactive protein and cardiovascular disease.
62. Cardiovascular disease in patients with end-stage renal disease on hemodialysis in a developing country.
63. Cardiovascular disease in kidney donors: matched cohort study.
64. Randomised clinical trial of an intensive intervention in the primary care setting of patients with high plasma fibrinogen in the primary prevention of cardiovascular disease.
65. Global cardiovascular disease risk assessment in United States adults with diabetes.
66. Exercise Effects on Risk of Cardiovascular Disease among Iranian Women.
67. Physical activity and cardiovascular disease risk factors among young and middle-aged men in urban Mwanza, Tanzania.
68. Tooth loss and cardiovascular disease mortality risk--results from the Scottish Health Survey.
69. Comparison of cardiovascular disease risk in two main forms of periodontitis.
70. The association between study characteristics and outcome in the relation between job stress and cardiovascular disease - a multilevel meta-regression analysis.
71. The metabolic syndrome among patients with cardiovascular disease in Accra, Ghana.
72. Work-related cardiovascular disease risk factors using a socioecological approach: implications for practice and research.
73. Summaries for patients: Does routinely assessing family history improve detection of patients at high risk for cardiovascular disease?
74. Effects of some common food constituents on cardiovascular disease.
75. Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease.
76. Sedentary behaviour and biomarkers for cardiovascular disease and diabetes in mid-life: the role of television-viewing and sitting at work.
77. Latent constructs in psychosocial factors associated with cardiovascular disease: an examination by race and sex.
78. Effect of elevated total cholesterol level and hypertension on the risk of fatal cardiovascular disease: a cohort study of Chinese steelworkers.
79. Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis.
80. Plant sterols and cardiovascular disease: a systematic review and meta-analysis.
81. A Database of Gene-Environment Interactions Pertaining to Blood Lipid Traits, Cardiovascular Disease and Type 2 Diabetes.
82. The Williams-Beuren Syndrome-a window into genetic variants leading to the development of cardiovascular disease.
83. Mesenchymal stem cells and cardiovascular disease: a bench to bedside roadmap.
84. Nanomedical Theranostics in Cardiovascular Disease.
85. Predicting and preventing cardiovascular disease in HIV-infected patients.
86. Inflammation and related biomarkers in cardiovascular disease.
87. One more look at guidelines for primary and secondary prevention of cardiovascular disease in women.
88. Diagnosis of cardiovascular disease in patients with chronic kidney disease.
89. Design and rationale of the tobacco, exercise and diet messages (TEXT ME) trial of a text message-based intervention for ongoing prevention of cardiovascular disease in people with coronary disease: a randomised controlled trial protocol.
90. Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program.
91. Co-morbid depression is associated with poor work outcomes in persons with cardiovascular disease (CVD): A large, nationally representative survey in the Australian population.
92. SDF-1α and CXCR4 as therapeutic targets in cardiovascular disease.
93. Heme oxygenase-1 in inflammation and cardiovascular disease.
94. GRK2 and β-arrestins in cardiovascular disease: Something old, something new.
95. The launch of American Journal of Cardiovascular Disease.
96. Summaries for patients: Risk for death from cardiovascular disease in women with obstructive sleep apnea.
97. Prevalence of cardiovascular disease and risk factors in a rural district of Beijing, China: a population-based survey of 58,308 residents.
98. Perivascular Fat and the Microcirculation: Relevance to Insulin Resistance, Diabetes, and Cardiovascular Disease.
99. Melatonin and cardiovascular disease: myth or reality?
100. Cardiovascular disease-related lifestyle factors and longevity.
101. An ecological model using promotores de salud to prevent cardiovascular disease on the US-Mexico border: the HEART project.
102. Evaluation of association between intima-media thickness of the carotid artery and risk factors for cardiovascular disease in patients on maintenance hemodialysis.
103. Sub-optimal achievement of guideline-derived lipid goals in management of diabetes patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies.
104. Activin A and cardiovascular disease in type 2 diabetes mellitus.
105. Epigenetic modifications in cardiovascular disease.
106. Anthropometric measures as predictors of cardiovascular disease risk factors in the urban population of Iran.
107. Different anthropometric adiposity measures and their association with cardiovascular disease risk factors: a meta-analysis.
108. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
109. Insomnia symptoms and cardiovascular disease among older American Indians: the Native Elder Care Study.
110. Cardiovascular disease research in Latin America: a comparative bibliometric analysis.
111. Predictors of health-related quality of life in patients at risk for cardiovascular disease in European primary care.
112. Association between mean platelet volume and coronary artery calcification in patients without overt cardiovascular disease: an observational study.
113. A systematic review of economic evaluations of interventions to tackle cardiovascular disease in low- and middle-income countries.
114. Management of cardiovascular disease in chronic kidney disease: implications for managed care.
115. Optimizing outcomes in patients with cardiovascular disease and chronic kidney disease.
116. Recognizing the link between chronic kidney disease and cardiovascular disease.
117. Anthocyanins in cardiovascular disease.
118. Lifestyle risk factors and cardiovascular disease in cubans and cuban americans.
119. Clinical use of aspirin in treatment and prevention of cardiovascular disease.
120. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population.
121. Estrogen and cardiovascular disease: aging and estrogen loss at the heart of the matter?
122. Undernutrition during fetal life and the risk of cardiovascular disease in adulthood.
123. Multi-Country analysis of palm oil consumption and cardiovascular disease mortality for countries at different stages of economic development: 1980-1997.
124. Protocol for the modeling the epidemiologic transition study: a longitudinal observational study of energy balance and change in body weight, diabetes and cardiovascular disease risk.
125. Effects of rose hip intake on risk markers of type 2 diabetes and cardiovascular disease: a randomized, double-blind, cross-over investigation in obese persons.
126. Association between cholecystectomy for gallstone disease and risk factors for cardiovascular disease.
127. Prevalence of comorbid conditions with aging among patients with diabetes and cardiovascular disease.
128. Genetics and tailored therapy in cardiovascular disease.
129. The relative impact of vision impairment and cardiovascular disease on quality of life: the example of pseudoxanthoma elasticum.
130. A comparison of the recognition of overwork-related cardiovascular disease in Japan, Korea, and Taiwan.
131. Randomized controlled trial for an effect of catechin-enriched green tea consumption on adiponectin and cardiovascular disease risk factors.
132. Lead concentrations in relation to multiple biomarkers of cardiovascular disease: the Normative Aging Study.
133. A preliminary study on the prevalence of cardiovascular disease risk factors in selected rural communities in samarahan and kuching division, sarawak, malaysia.
134. Genomics of cardiovascular disease.
135. [Overweight and obesity in prepubertal schoolchildren: the association with low birth weight and family antecedents of cardiovascular disease. Embu - metropolitan region of São Paulo, 2006].
136. Imaging assessment of cardiovascular disease in systemic lupus erythematosus.
137. Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance.
138. Status of novel cardiovascular risk factor and cardiovascular disease risk in an urban Cuban population--a pilot study.
139. Calcium supplementation, vitamin K status and cardiovascular disease: an additional point.
140. Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial.
141. Cardiovascular disease in the elderly: comment.
142. Type 2 diabetes, cardiovascular disease and the utilisation of primary care in urban and regional settings.
143. What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study.
144. Extracellular/circulating microRNAs and their potential role in cardiovascular disease.
145. [Cholesteryl ester transfer protein inhibition in the management of atherosclerotic cardiovascular disease: second act "A rebirth of hope"].
146. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study.
147. Screening for cardiovascular disease using age alone: reflections on a paper peer-reviewed as both 'radical' and 'unsurprising'.
148. Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well?
149. Sleep duration and sleep quality in relation to 12-year cardiovascular disease incidence: the MORGEN study.
150. Short and long term effects of a lifestyle intervention for construction workers at risk for cardiovascular disease: a randomized controlled trial.
151. Associations of preexisting depression and anxiety with hospitalization in patients with cardiovascular disease.
152. Recent methods for polygenic analysis of genome-wide data implicate an important effect of common variants on cardiovascular disease risk.
153. The effect of chromosome 9p21 variants on cardiovascular disease may be modified by dietary intake: evidence from a case/control and a prospective study.
154. An overview of lymphatic vessels and their emerging role in cardiovascular disease.
155. Preface to the Journal of Cardiovascular Disease Research, third issue 2011.
156. Trends in adult cardiovascular disease risk factors and their socio-economic patterning in the Scottish population 1995-2008: cross-sectional surveys.
157. Detection and follow-up of cardiovascular disease and risk factors in the Southern Cone of Latin America: the CESCAS I study.
158. Distribution of 10-year and lifetime predicted risk for cardiovascular disease in the Indian Sentinel Surveillance Study population (cross-sectional survey results).
159. Clinical Psychology and Cardiovascular Disease: An Up-to-Date Clinical Practice Review for Assessment and Treatment of Anxiety and Depression.
160. Body mass index and screening for cardiovascular disease risk.
161. Comparison of primary care models in the prevention of cardiovascular disease - a cross sectional study.
162. The changing profile of the cardiovascular patient and the future of cardiovascular disease treatment and prevention: British Columbia as an example.
163. Reducing cardiovascular disease risk using patient navigators, Denver, Colorado, 2007-2009.
164. Causal beliefs and perceptions of risk for diabetes and cardiovascular disease, The Netherlands, 2007.
165. Caring for others, but not themselves: implications for health care interventions in women with cardiovascular disease.
166. Subchronic pulmonary pathology, iron overload, and transcriptional activity after Libby amphibole exposure in rat models of cardiovascular disease.
167. Saturated fat, carbohydrates and cardiovascular disease.
168. Framingham risk prediction equations for incidence of cardiovascular disease using detailed measures for smoking.
169. Childhood cardiovascular risk factors in South Asians: A cause of concern for adult cardiovascular disease epidemic.
170. Developing high performance lipoprotein density profiling for use in clinical studies relating to cardiovascular disease.
171. Hyperpolarized magnetic resonance: a novel technique for the in vivo assessment of cardiovascular disease.
172. Cardiovascular disease and primary ovarian insufficiency.
173. Frailty in Patients with Cardiovascular Disease: Why, When, and How to Measure.
174. Computational fluid dynamics in cardiovascular disease.
175. Association of ADIPOR2 gene variants with cardiovascular disease and type 2 diabetes risk in individuals with impaired glucose tolerance: the Finnish Diabetes Prevention Study.
176. Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors--United States, 2011.
177. United Nations' dietary policies to prevent cardiovascular disease.
178. Heavy metal poisoning and cardiovascular disease.
179. Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative.
180. Implications for reproductive medicine: Sex differences in cardiovascular disease.
181. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk.
182. Cancer and cardiovascular disease.
183. Moderate weight reduction in an outpatient obesity intervention program significantly reduces insulin resistance and risk factors for cardiovascular disease in severely obese adolescents.
184. A systematic overview of prospective cohort studies of cardiovascular disease in sub-Saharan Africa.
185. Cardiovascular disease prevention in Ghana: feasibility of a faith-based organizational approach.
186. [Psychiatric and behavioral aspects of cardiovascular disease: epidemiology, mechanisms, and treatment].
187. Cardiovascular disease in systemic sclerosis--an emerging association?
188. Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension.
189. Maternal smoking during pregnancy and risk factors for cardiovascular disease in adulthood.
190. Calcium supplementation, osteoporosis and cardiovascular disease.
191. Drug discovery for improvement of chronic kidney disease and cardiovascular disease.
192. Analysis of cardiovascular disease in Chinese inpatients with chronic kidney disease.
193. Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.
194. A registry-based follow-up study, comparing the incidence of cardiovascular disease in native Danes and immigrants born in Turkey, Pakistan and the former Yugoslavia: do social inequalities play a role?
195. MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease.
196. Association of incident cardiovascular disease with periodic limb movements during sleep in older men: outcomes of sleep disorders in older men (MrOS) study.
197. Clinical Implications of Lipid Genetics for Cardiovascular Disease.
198. Clinical significance of visceral fat reduction through health education in preventing atherosclerotic cardiovascular disease - Lesson from the Amagasaki Visceral Fat Study: A Japanese perspective.
199. CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study.
200. Cardiovascular Disease-Related Lifestyle Factors among People with Type 2 Diabetes in Pakistan: A Multicentre Study for the Prevalence, Clustering, and Associated Sociodemographic Determinants.
201. A cardiovascular disease risk factor screening program designed to reach rural residents of Maine, USA.
202. The research on endothelial function in women and men at risk for cardiovascular disease (REWARD) study: methodology.
203. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease [Internet].
204. Relationship between Depressive Symptoms and Cardiovascular Disease Risk Factors in African American Individuals.
205. Internet-based support for cardiovascular disease management.
206. Systematic Review of Cardiovascular Disease Risk Assessment Tools [Internet].
207. Effect of gene environment interactions on lung function and cardiovascular disease in COPD.
208. Should eGFR and albuminuria be added to the Framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction.
209. Grape extract and α-Tocopherol effect in cardiovascular disease model of Apo E -/- Mice.
210. Trends in risk factors for cardiovascular disease among Iranian adolescents: the Tehran Lipid and Glucose Study, 1999-2008.
211. Evidence-based risk assessment and recommendations for physical activity clearance: established cardiovascular disease (1) (1) This paper is one of a selection of papers published in this Special Issue, entitled Evidence-based risk assessment and recommendations for physical activity clearance, and has undergone the Journal's usual peer review process.
212. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study.
213. The clinical impact of circulating caspase-3 p17 level: a potential new biomarker for myocardial injury and cardiovascular disease.
214. Post-traumatic Stress Disorder and Cardiovascular Disease.
215. Depression and outcomes in hospitalized Japanese patients with cardiovascular disease. - Prospective single-center observational study-.
216. How to stay heart healthy in 2011: considerations for the primary prevention of cardiovascular disease in women.
217. Preparing nurses for leadership roles in cardiovascular disease prevention.
218. The global burden of cardiovascular disease.
219. Nurse-based models for cardiovascular disease prevention: from research to clinical practice.
220. Global cardiovascular disease prevention: a call to action for nursing. Foreword.
221. Global cardiovascular disease prevention: a call to action for nursing: community-based and public health prevention initiatives.
222. A life course approach to cardiovascular disease prevention.
223. Global cardiovascular disease prevention: a call to action for nursing: multilevel policies.
224. Global cardiovascular disease prevention: a call to action for nursing: the global burden of cardiovascular disease. Introduction.
225. Alcohol consumption and risk of all-cause and cardiovascular disease mortality in men.
226. Relationship between medication use and cardiovascular disease health outcomes in the Jackson Heart Study.
227. Novel therapeutic targets for preserving a healthy endothelium: strategies for reducing the risk of vascular and cardiovascular disease.
228. Lung cancer and cardiovascular disease mortality associated with ambient air pollution and cigarette smoke: shape of the exposure-response relationships.
229. The link between periodontal disease and cardiovascular disease: How far we have come in last two decades ?
230. New molecular mechanisms for cardiovascular disease:transcriptional pathways and novel therapeutic targets in heart failure.
231. New molecular mechanisms for cardiovascular disease:blood flow sensing mechanism in vascular endothelial cells.
232. New molecular mechanisms for cardiovascular disease: contribution of endothelium-derived hyperpolarizing factor in the regulation of vasoconstriction in peripheral resistance arteries.
233. New molecular mechanisms for cardiovascular disease: cardiac hypertrophy and cell-volume regulation.
234. New molecular mechanisms for cardiovascular disease: preface.
235. [The frequency of cardiovascular disease-associated risk factors in a university student population].
236. Examination of the Association between Insufficient Sleep and Cardiovascular Disease and Diabetes by Race/Ethnicity.
237. Cardiovascular disease by diabetes status in five ethnic minority groups compared to ethnic Norwegians.
238. Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease.
239. Carotid intima media thickness as a measure of cardiovascular disease burden in nigerian africans with hypertension and diabetes mellitus.
240. Management of High Blood Pressure in Those without Overt Cardiovascular Disease Utilising Absolute Risk Scores.
241. The rheological properties of blood and the risk of cardiovascular disease in patients with obstructive sleep apnea syndrome (OSAS).
242. Use of vitamin supplements and risk of total cancer and cardiovascular disease among the Japanese general population: a population-based survey.
243. Identification of EPAC (Exchange Protein Activated by cAMP) bioinformatically as a potential signalling biomarker in Cardiovascular Disease (CVD) and its molecular docking by a lead molecule.
244. Circulating adiponectin levels are lower in Latino versus non-Latino white patients at risk for cardiovascular disease, independent of adiposity measures.
245. Does chronic kidney disease modify the association between body mass index and cardiovascular disease risk factors.
246. Cardiovascular disease in the elderly.
247. Mesenchymal stromal cells for cardiovascular disease.
248. Journal of Cardiovascular Disease Research celebrates its anniversary.
249. Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial.
250. Cardiovascular disease prevention in women: are we up to date?
251. Reconsidering low-dose aspirin therapy for cardiovascular disease: a study protocol for physician and patient behavioral change.
252. Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study.
253. Classical risk factors of cardiovascular disease among Chinese male steel workers: a prospective cohort study for 20 years.
254. [Correlation between cardiovascular risk factors and the expression of cardiovascular disease related genes in cynomolgus monkeys].
255. Long-term exposure to ambient air pollution and mortality due to cardiovascular disease and cerebrovascular disease in Shenyang, China.
256. A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries.
257. Cardiovascular disease risk factors in homeless people.
258. Association of candy consumption with body weight measures, other health risk factors for cardiovascular disease, and diet quality in US children and adolescents: NHANES 1999-2004.
259. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease.
260. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study.
261. Japanese dietary lifestyle and cardiovascular disease.
262. Calcium, vitamin D and cardiovascular disease.
263. Association of DDAH2 gene polymorphism with cardiovascular disease in Egyptian patients.
264. Nutritional supplementation during pregnancy and offspring cardiovascular disease risk in The Gambia.
265. Development of the Champlain primary care cardiovascular disease prevention and management guideline: tailoring evidence to community practice.
266. Androgens exert sexually dimorphic effects on angiogenesis: novel insight into the relationship between androgens and cardiovascular disease.
267. Indices of kidney damage and cardiovascular disease risk factors in a semiurban community of iloye, South-west Nigeria.
268. A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population.
269. Oxidative stress and its association with cardiovascular disease in chronic renal failure patients.
270. MicroRNAs in cardiovascular disease.
271. Television viewing and incident cardiovascular disease: prospective associations and mediation analysis in the EPIC Norfolk Study.
272. Implicit measures of early-life family conditions: relationships to psychosocial characteristics and cardiovascular disease risk in adulthood.
273. [Factors associated with uncontrolled hypertension in patients with and without cardiovascular disease].
274. Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1.
275. Endothelial nitric oxide synthase (eNOS) variants in cardiovascular disease: pharmacogenomic implications.
276. Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes.
277. Evidence of lung function for stratification of cardiovascular disease risk.
278. A new paradigm in the treatment of the cardiovascular disease continuum: focus on prevention.
279. Predictive utility of the Framingham general cardiovascular disease risk profile for cognitive function: evidence from the Whitehall II study.
280. The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control.
281. Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease.
282. NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies.
283. Behavioral Counseling to Promote Physical Activity and a Healthful Diet to Prevent Cardiovascular Disease in Adults: Update of the Evidence for the U.S. Preventive Services Task Force [Internet].
284. [Body mass index to the cardiovascular disease risk screening in infancy].
285. Epigenetic modifications: basic mechanisms and role in cardiovascular disease.
286. Screening for future cardiovascular disease using age alone compared with multiple risk factors and age.
287. The prevalence of natural health product use in patients with acute cardiovascular disease.
288. The relationship between indices of iron status and selected anthropometric cardiovascular disease risk markers in an African population: the THUSA study.
289. Astaxanthin: a potential therapeutic agent in cardiovascular disease.
290. Comparison of Measures of Adiposity in Identifying Cardiovascular Disease Risk Among Ethiopian Adults.
291. Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study.
292. Assessment and management of cardiovascular disease in patients with chronic kidney disease.
293. Association of brain-type natriuretic protein and cardiac troponin I with incipient cardiovascular disease in chimpanzees (Pan troglodytes).
294. Relationship of cardiovascular disease to stress and vital exhaustion in an urban, midwestern police department.
295. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease.
296. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
297. Derivation of human induced pluripotent stem cells for cardiovascular disease modeling.
298. Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States.
299. A cluster randomised school-based lifestyle intervention programme for the prevention of childhood obesity and related early cardiovascular disease (JuvenTUM 3).
300. Mechanisms of resolution of inflammation: a focus on cardiovascular disease.
301. Amino-terminal pro-B-type brain natriuretic peptide: screening for cardiovascular disease in the setting of alcoholism.
302. Geographic differences in allele frequencies of susceptibility SNPs for cardiovascular disease.
303. Community Implementation and Translation of Kaiser Permanente's Cardiovascular Disease Risk-Reduction Strategy.
304. Multiple health behaviors in an ethnically diverse sample of adults with risk factors for cardiovascular disease.
305. Effect of muscadine grape seed supplementation on vascular function in subjects with or at risk for cardiovascular disease: a randomized crossover trial.
306. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
307. Renin and cardiovascular disease: Worn-out path, or new direction.
308. Physical activity and risk of fatal or non-fatal cardiovascular disease among CVD survivors: the JMS cohort study.
309. Epidemiology of cardiovascular disease in women: risk, advances, and alarms.
310. Community prevalence of ideal cardiovascular health, by the American Heart Association definition, and relationship with cardiovascular disease incidence.
311. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.
312. Perspectives on the crisis and challenge of cardiovascular disease in the diverse Asian populations of California.
313. Measures of adiposity and cardiovascular disease risk factors, New York City Health and Nutrition Examination Survey, 2004.
314. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
315. Lifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in men. The Cooper Center Longitudinal Study.
316. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study.
317. Perivascular adipose tissue and its role in type 2 diabetes and cardiovascular disease.
318. The sense and nonsense of direct-to-consumer genetic testing for cardiovascular disease.
319. Monitoring of incidence, severity, and causality of adverse drug reactions in hospitalized patients with cardiovascular disease.
320. Particulate matter exposures, mortality, and cardiovascular disease in the health professionals follow-up study.
321. Guidelines for assessment of cardiovascular disease in life insurance.
322. Rest/activity rhythms and cardiovascular disease in older men.
323. Ministry of health clinical practice guidelines: screening of cardiovascular disease and risk factors.
324. [Assessment and management of cardiovascular disease in patients with chronic kidney disease].
325. Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes.
326. Endothelial function in resistance and conduit arteries and 5-year risk of cardiovascular disease.
327. Cardiovascular disease prevention in rural Nigeria in the context of a community based health insurance scheme: QUality Improvement Cardiovascular care Kwara-I (QUICK-I).
328. Predicting cardiovascular disease risk factors in midadulthood from childhood body mass index: utility of different cutoffs for childhood body mass index.
329. Mercury exposure and risk of cardiovascular disease in two U.S. cohorts.
330. Role of platelets and antiplatelet therapy in cardiovascular disease.
331. Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality.
332. Effects on cardiovascular disease risk of a web-based health risk assessment with tailored health advice: a follow-up study.
333. Gene-air pollution interaction and cardiovascular disease: a review.
334. Variations in cardiovascular disease under-diagnosis in England: national cross-sectional spatial analysis.
335. Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad.
336. Association of incident cardiovascular disease with progression of sleep-disordered breathing.
337. Diabetes and hypertension and atherosclerotic cardiovascular disease: related or separate entities often found together.
338. Adequacy of reporting monitoring regimens of risk factors for cardiovascular disease in clinical guidelines: systematic review.
339. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies.
340. Is vitamin D deficiency a risk factor for ischemic heart disease in patients with established cardiovascular disease? 10-year follow-up of the Nova Scotia Health Survey.
341. Differences in cardiovascular disease risk factors by weight history: the Aerobics Center Longitudinal Study.
342. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
343. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
344. Frequency of citrus fruit intake is associated with the incidence of cardiovascular disease: the Jichi Medical School cohort study.
345. Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease.
346. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association.
347. Letter by Thornton regarding article, "Whole-grain, cereal fiber, bran, and germ intake and the risks of all-cause and cardiovascular disease-specific mortality among women with type 2 diabetes mellitus".
348. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States.
349. Review of tools of cardiovascular disease risk stratification: interpretation, customisation and application in clinical practice.
350. Usefulness of respiratory variation of inferior vena cava diameter for estimation of elevated central venous pressure in children with cardiovascular disease.
351. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers.
352. Potassium intake, stroke, and cardiovascular disease a meta-analysis of prospective studies.
353. The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.
354. Does vitamin D deficiency contribute to increased rates of cardiovascular disease and type 2 diabetes in African Americans?
355. Premature cardiovascular disease in patients with systemic lupus erythematosus influences survival after renal transplantation.
356. Migraine and cardiovascular disease.
357. Utility of B-type natriuretic Peptide for predicting perioperative cardiovascular events in patients without history of cardiovascular disease undergoing major non-cardiac surgery.
358. Epidemiologic review of long-term, low-level exposure to environmental chemicals and cardiovascular disease: an exposure-response relationship.
359. Diabetes and cardiovascular disease.
360. Haem oxygenase-1 and cardiovascular disease: mechanisms and therapeutic potential.
361. Rice intake is associated with reduced risk of mortality from cardiovascular disease in Japanese men but not women.
362. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis.
363. [HDL: the yin-yang of cardiovascular disease].
364. Missed opportunities in cardiovascular disease prevention?: low rates of hypertension recognition for women at medicine and obstetrics-gynecology clinics.
365. The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice.
366. Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management.
367. Genetics of hypertension and cardiovascular disease.
368. Waist Circumference, Body Mass Index, and Other Measures of Adiposity in Predicting Cardiovascular Disease Risk Factors among Peruvian Adults.
369. Pulse pressure predicts incident cardiovascular disease but not diabetic nephropathy in patients with type 1 diabetes (The FinnDiane Study).
370. Multiple risk factor intervention to prevent cardiovascular disease. A high powered and evidence based approach.
371. Letter by D'Alessandra et al regarding article, "Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease".
372. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association.
373. Clinical preventive services for patients at risk for cardiovascular disease, National Ambulatory Medical Care Survey, 2005-2006.
374. Periodontal treatment effects on endothelial function and cardiovascular disease biomarkers in subjects with chronic periodontitis: protocol for a randomized clinical trial.
375. Age at quitting smoking as a predictor of risk of cardiovascular disease incidence independent of smoking status, time since quitting and pack-years.
376. Lifestyle and cardiovascular disease in Japan.
377. Translating evidence into policy for cardiovascular disease control in India.
378. Cardiovascular disease risk and the need for prevention after paraplegia determined by conventional multifactorial risk models: the Stockholm spinal cord injury study.
379. Re: "Risk of incident cardiovascular disease among users of smokeless tobacco in the Atherosclerosis Risk in Communities (ARIC) Study".
380. Musculoskeletal comorbidities in cardiovascular disease, diabetes and respiratory disease: the impact on activity limitations; a representative population-based study.
381. Cardiovascular Disease.
382. Sleep duration as a risk factor for cardiovascular disease- a review of the recent literature.
383. Empirical derivation to improve the definition of the metabolic syndrome in the evaluation of cardiovascular disease risk.
384. Early identification and preventive care for elevated cardiovascular disease risk within a remote Australian Aboriginal primary health care service.
385. Lifestyle practices and cardiovascular disease mortality in the elderly: the leisure world cohort study.
386. Trends in cardiovascular risk factor levels in the Minnesota Heart Survey (1980-2002) as compared with the National Health and Nutrition Examination Survey (1976-2002): A partial explanation for Minnesota's low cardiovascular disease mortality?
387. The ACC looks globally to tackle cardiovascular disease.
388. Insights into the development and treatment of cardiovascular disease: a role for animal models.
389. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010?
390. Adherence index based on the AHA 2006 diet and lifestyle recommendations is associated with select cardiovascular disease risk factors in older Puerto Ricans.
391. Methylenetetrahydrofolate reductase variants associated with hypertension and cardiovascular disease interact with dietary polyunsaturated fatty acids to modulate plasma homocysteine in puerto rican adults.
392. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
393. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
394. Preface to the fourth issue of Journal of Cardiovascular Disease Research.
395. Telomere biology in cardiovascular disease - role of insulin sensitivity in diabetic hearts.
396. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.
397. Insulin resistance and cardiovascular disease risk factors in subjects with prehypertension.
398. Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease.
399. Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease.
400. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.